Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Catherine Kim; Carrie Karvonen-Gutierrez; Shengchun Kong; Valerie Arends; Michael Steffes; Daniel S. McConnell; John F. Randolph; Siobán D. Harlow

doi:10.1016/j.fertnstert.2016.07.009

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Catherine Kim, Carrie Karvonen-Gutierrez, Shengchun Kong, Valerie Arends, Michael Steffes, Daniel S. McConnell, John F. Randolph, Siobán D. Harlow

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Objective To compare concentrations of antimüllerian hormone (AMH) in women with and without type 1 diabetes. Design Cross-sectional analysis of longitudinal studies, adjusting for repeated measures. Setting Not applicable. Patient(s) Women aged 30–45 years who had not undergone oophorectomy, hysterectomy, or natural menopause at the time of AMH measurement were included (n = 376 in the Michigan Bone Health and Metabolism Study and n = 321 in the Epidemiology of Interventions and Complications Study). Linear mixed regression was used to evaluate whether AMH concentrations differed by diabetes status, adjusting for repeated measurements of AMH within individual women, body mass index, smoking status, and oral contraceptive use. Intervention(s) None. Main Outcome Measure(s) Concentrations of AMH. Result(s) In unadjusted comparisons, women with and without diabetes had similar median AMH values before 35 years of age, although women with type 1 diabetes had a lower proportion of women with elevated AMH concentrations (≥5.0 ng/dL). After adjustment for covariates and multiple observations per woman, log AMH concentrations were significantly lower among women with type 1 diabetes compared with women without diabetes (β-coefficient −1.27, 95% confidence interval [−2.18, −0.36] in fully adjusted models) before 35 years of age. Conclusion(s) Before 35 years of age, women with type 1 diabetes have lower AMH levels than women without diabetes. Further investigation is needed to determine the etiologies of this difference and how it may contribute to reproductive disorders among women with type 1 diabetes.

Original language	English (US)
Pages (from-to)	1446-1452
Number of pages	7
Journal	Fertility and Sterility
Volume	106
Issue number	6
DOIs	https://doi.org/10.1016/j.fertnstert.2016.07.009
State	Published - Nov 1 2016

Bibliographical note

Funding Information:
Assay kits for the measurement of antimüllerian hormone in the Michigan Bone Health and Metabolism Study were provided at no charge by Beckman Coulter. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications were supported by U01 Cooperative Agreement grants (1982–1993, 2011–2016) and contracts (1982–2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (current grant numbers U01 DK094176 and U01 DK094157), and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993–2007), and the Clinical Translational Science Center Program (2006–present), Bethesda, Maryland. Additional support for this work was provided by National Institutes of Health (DP3 DK098129). The Michigan Bone Health and Metabolism Study received support from the National Institute of Arthritis and Muscular Skeletal and Skin Diseases (AG051384). S.K. was an employee at Purdue University during the completion of the manuscript. S.D.H. gratefully acknowledges use of the services and facilities of the Population Studies Center at the University of Michigan, funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development Center Grant R24 HD041028. C.K.-G. is partially supported by a Claude Pepper Career Development Award.

Publisher Copyright:
© 2016

Keywords

Ovarian hormones
reproductive endocrinology
type 1 diabetes
women's health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.fertnstert.2016.07.009

OpenUrl availability

Full text

Cite this

Kim, C., Karvonen-Gutierrez, C., Kong, S., Arends, V., Steffes, M., McConnell, D. S., Randolph, J. F., & Harlow, S. D. (2016). Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study. Fertility and Sterility, 106(6), 1446-1452. https://doi.org/10.1016/j.fertnstert.2016.07.009

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study. / Kim, Catherine; Karvonen-Gutierrez, Carrie; Kong, Shengchun et al.
In: Fertility and Sterility, Vol. 106, No. 6, 01.11.2016, p. 1446-1452.

Research output: Contribution to journal › Article › peer-review

Kim, C, Karvonen-Gutierrez, C, Kong, S, Arends, V, Steffes, M, McConnell, DS, Randolph, JF & Harlow, SD 2016, 'Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study', Fertility and Sterility, vol. 106, no. 6, pp. 1446-1452. https://doi.org/10.1016/j.fertnstert.2016.07.009

@article{6b4457e3e4ec4f01af13371004b46c8f,

title = "Antim{\"u}llerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study",

abstract = "Objective To compare concentrations of antim{\"u}llerian hormone (AMH) in women with and without type 1 diabetes. Design Cross-sectional analysis of longitudinal studies, adjusting for repeated measures. Setting Not applicable. Patient(s) Women aged 30–45 years who had not undergone oophorectomy, hysterectomy, or natural menopause at the time of AMH measurement were included (n = 376 in the Michigan Bone Health and Metabolism Study and n = 321 in the Epidemiology of Interventions and Complications Study). Linear mixed regression was used to evaluate whether AMH concentrations differed by diabetes status, adjusting for repeated measurements of AMH within individual women, body mass index, smoking status, and oral contraceptive use. Intervention(s) None. Main Outcome Measure(s) Concentrations of AMH. Result(s) In unadjusted comparisons, women with and without diabetes had similar median AMH values before 35 years of age, although women with type 1 diabetes had a lower proportion of women with elevated AMH concentrations (≥5.0 ng/dL). After adjustment for covariates and multiple observations per woman, log AMH concentrations were significantly lower among women with type 1 diabetes compared with women without diabetes (β-coefficient −1.27, 95% confidence interval [−2.18, −0.36] in fully adjusted models) before 35 years of age. Conclusion(s) Before 35 years of age, women with type 1 diabetes have lower AMH levels than women without diabetes. Further investigation is needed to determine the etiologies of this difference and how it may contribute to reproductive disorders among women with type 1 diabetes.",

keywords = "Ovarian hormones, reproductive endocrinology, type 1 diabetes, women's health",

author = "Catherine Kim and Carrie Karvonen-Gutierrez and Shengchun Kong and Valerie Arends and Michael Steffes and McConnell, {Daniel S.} and Randolph, {John F.} and Harlow, {Siob{\'a}n D.}",

note = "Funding Information: Assay kits for the measurement of antim{\"u}llerian hormone in the Michigan Bone Health and Metabolism Study were provided at no charge by Beckman Coulter. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications were supported by U01 Cooperative Agreement grants (1982–1993, 2011–2016) and contracts (1982–2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (current grant numbers U01 DK094176 and U01 DK094157), and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993–2007), and the Clinical Translational Science Center Program (2006–present), Bethesda, Maryland. Additional support for this work was provided by National Institutes of Health (DP3 DK098129). The Michigan Bone Health and Metabolism Study received support from the National Institute of Arthritis and Muscular Skeletal and Skin Diseases (AG051384). S.K. was an employee at Purdue University during the completion of the manuscript. S.D.H. gratefully acknowledges use of the services and facilities of the Population Studies Center at the University of Michigan, funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development Center Grant R24 HD041028. C.K.-G. is partially supported by a Claude Pepper Career Development Award. Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.fertnstert.2016.07.009",

language = "English (US)",

volume = "106",

pages = "1446--1452",

journal = "Fertility and Sterility",

issn = "0015-0282",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Antimüllerian hormone among women with and without type 1 diabetes

T2 - the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

AU - Kim, Catherine

AU - Karvonen-Gutierrez, Carrie

AU - Kong, Shengchun

AU - Arends, Valerie

AU - Steffes, Michael

AU - McConnell, Daniel S.

AU - Randolph, John F.

AU - Harlow, Siobán D.

N1 - Funding Information: Assay kits for the measurement of antimüllerian hormone in the Michigan Bone Health and Metabolism Study were provided at no charge by Beckman Coulter. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications were supported by U01 Cooperative Agreement grants (1982–1993, 2011–2016) and contracts (1982–2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (current grant numbers U01 DK094176 and U01 DK094157), and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993–2007), and the Clinical Translational Science Center Program (2006–present), Bethesda, Maryland. Additional support for this work was provided by National Institutes of Health (DP3 DK098129). The Michigan Bone Health and Metabolism Study received support from the National Institute of Arthritis and Muscular Skeletal and Skin Diseases (AG051384). S.K. was an employee at Purdue University during the completion of the manuscript. S.D.H. gratefully acknowledges use of the services and facilities of the Population Studies Center at the University of Michigan, funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development Center Grant R24 HD041028. C.K.-G. is partially supported by a Claude Pepper Career Development Award. Publisher Copyright: © 2016

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective To compare concentrations of antimüllerian hormone (AMH) in women with and without type 1 diabetes. Design Cross-sectional analysis of longitudinal studies, adjusting for repeated measures. Setting Not applicable. Patient(s) Women aged 30–45 years who had not undergone oophorectomy, hysterectomy, or natural menopause at the time of AMH measurement were included (n = 376 in the Michigan Bone Health and Metabolism Study and n = 321 in the Epidemiology of Interventions and Complications Study). Linear mixed regression was used to evaluate whether AMH concentrations differed by diabetes status, adjusting for repeated measurements of AMH within individual women, body mass index, smoking status, and oral contraceptive use. Intervention(s) None. Main Outcome Measure(s) Concentrations of AMH. Result(s) In unadjusted comparisons, women with and without diabetes had similar median AMH values before 35 years of age, although women with type 1 diabetes had a lower proportion of women with elevated AMH concentrations (≥5.0 ng/dL). After adjustment for covariates and multiple observations per woman, log AMH concentrations were significantly lower among women with type 1 diabetes compared with women without diabetes (β-coefficient −1.27, 95% confidence interval [−2.18, −0.36] in fully adjusted models) before 35 years of age. Conclusion(s) Before 35 years of age, women with type 1 diabetes have lower AMH levels than women without diabetes. Further investigation is needed to determine the etiologies of this difference and how it may contribute to reproductive disorders among women with type 1 diabetes.

AB - Objective To compare concentrations of antimüllerian hormone (AMH) in women with and without type 1 diabetes. Design Cross-sectional analysis of longitudinal studies, adjusting for repeated measures. Setting Not applicable. Patient(s) Women aged 30–45 years who had not undergone oophorectomy, hysterectomy, or natural menopause at the time of AMH measurement were included (n = 376 in the Michigan Bone Health and Metabolism Study and n = 321 in the Epidemiology of Interventions and Complications Study). Linear mixed regression was used to evaluate whether AMH concentrations differed by diabetes status, adjusting for repeated measurements of AMH within individual women, body mass index, smoking status, and oral contraceptive use. Intervention(s) None. Main Outcome Measure(s) Concentrations of AMH. Result(s) In unadjusted comparisons, women with and without diabetes had similar median AMH values before 35 years of age, although women with type 1 diabetes had a lower proportion of women with elevated AMH concentrations (≥5.0 ng/dL). After adjustment for covariates and multiple observations per woman, log AMH concentrations were significantly lower among women with type 1 diabetes compared with women without diabetes (β-coefficient −1.27, 95% confidence interval [−2.18, −0.36] in fully adjusted models) before 35 years of age. Conclusion(s) Before 35 years of age, women with type 1 diabetes have lower AMH levels than women without diabetes. Further investigation is needed to determine the etiologies of this difference and how it may contribute to reproductive disorders among women with type 1 diabetes.

KW - Ovarian hormones

KW - reproductive endocrinology

KW - type 1 diabetes

KW - women's health

UR - http://www.scopus.com/inward/record.url?scp=84993968410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993968410&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2016.07.009

DO - 10.1016/j.fertnstert.2016.07.009

M3 - Article

C2 - 27475411

AN - SCOPUS:84993968410

SN - 0015-0282

VL - 106

SP - 1446

EP - 1452

JO - Fertility and Sterility

JF - Fertility and Sterility

IS - 6

ER -

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this